Affibody Announces Broad Scientific Progress at EANM 2025

Solna, Sweden, September 30, 2025. Affibody AB (“Affibody”) today announced it will have substantial scientific presence at the 2025 Congress of the European Association of Nuclear Medicine (EANM), taking place October 4-8 in Barcelona. The company will be represented with five presentations covering key aspects of radiopharmaceutical development, underscoring Affibody’s diverse capabilities in the field. Affibodys innovative radiopharmaceutical pipeline will be featured in presentations covering: •the successful development of a cGMP-compliant manufacturing process for Affibody’s HER2-targeting radiotherapeutic candidate ABY-271 currently in a First-In-Human study; •clinical data on the PET imaging candidate tezatabep matraxetan (ABY-025) demonstrating highly specific visualization of HER2-positive lesions throughout the body in patients with metastatic breast cancer; •preclinical data on PET imaging of B7-H3 expression using Gallium-68-labelled Affibody® molecules showing high tumor-specific uptake; and •favorable preclinical biodistribution of a HER2-targeting Affibody® molecule labeled with the novel radionuclide Terbium-161. “We are delighted to have so many abstracts accepted at EANM 2025, a world-leading scientific event in nuclear medicine,” said David Bejker, Chief Executive Officer of Affibody. “This recognition underscores our position at the forefront of radiopharmaceutical development and reflects our dedication to turning scientific innovation into meaningful improvements for patients. We are grateful for the opportunity to collaborate with leading experts in the field, whose contributions are instrumental to our progress.” Abstract presentations Title: Preclinical PET Imaging of B7-H3 Expression Using Affibody Molecules Labelled with Positron-Emitting Gallium-68 Presenter: Prof. Fredrik Frejd, CSO Affibody Date and Time: October 6, 2025, 8:00 – 9:30 CEST Session: Technologists’ Track Oral Presentations 2 – Technologists Committee: Advanced Practice and Novel Solutions Format: Oral Presentation ID: OP-320 Title: Head-to-head comparison of ABD-fused Affibody Molecule labelled with Lu-177 and Tb-161 Presenter: Prof. Vladimir Tolmachev, Uppsala University Date and Time: October 8, 2025, 8:00 – 9:30 CEST Session: M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Antibodies and Co. Format: Oral Presentation ID: OP-764 Title: Development of a cGMP-compliant automated synthesis of the radiotherapeutic [177Lu]Lu-ABY-271: Enabling reliable radiolabelling for a first-in-human phase I study Presenter: Samar Omer, Department of Oncology-Pathology, Translational Theranostics Group, Karolinska Institutet Date and Time: October 6, 2025, 15:00 – 16:30 CEST Session: e-Poster Presentations Session 7 – Radiopharmaceutical Sciences Committee: Radiopharmacy e-Poster Presentations Session Radiochemistry and Quality Control Format: Oral e-Poster Presentation ID: EPS-154 Title: Visualising HER2 Heterogeneity in Advanced Breast Cancer using [68Ga]Ga-ABY-025 PET – a Single Centre Polish Experience Presenter: Prof. Gabriela Kramer-Marek, The Institute of Cancer Research, London and Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Session: e-Poster Area, B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast Format: e-Poster Presentation ID: EP-0207 Title: Diagnostic Contribution of [68Ga]Ga-ABY-025 PET in HER2-Positive Breast Cancer: Beyond [18F]FDG PET Presenter: Dr Ali Alhuseinalkhudhur, Department of Immunology, Genetics and Pathology, Uppsala University and Department of Surgical Sciences, Molecular imaging and medical physics, Uppsala University Session: e-Poster Area, B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others) Format: e-Poster Presentation ID: EP-0289 View the EANM abstracts here: https://eanm25.eanm.org/abstracts-book/

The release as fetched from its publisher. affibody.se ↗